NICE, SIGN & ESMO MELANOMA GUIDELINES

NICE Melanoma: assessment and management guideline [NG14] – 27 July 2022

 

This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.

In July 2022, they made new and updated recommendations on genetic testing, staging, surgery for stages 0 to III melanoma, anticancer treatment for people with stage III and IV melanoma, and follow-up.

You can find out more and read the updated guideline here.

This guideline includes recommendations on:

  • Communication and support
  • Managing vitamin D levels and drug treatment for other conditions
  • Assessing and staging melanoma
  • Managing stages 0 to II melanoma
  • Managing stage III melanoma
  • Treating in-transit metastases in stages III and IV melanoma
  • Managing stage IV and unresectable stage III melanoma
  • Follow-up treatment
Download the PDF version

SIGN146 Cutaneous melanoma: A national clinical guideline. Updated August 2023

 

This national clinical guideline was originally published in January 2017 and updated August 2023.

This guideline provides advice on the management of adults with melanoma. It covers all stages of the patient’s pathway of care, from preventing melanoma to early recognition, treatment and follow up.

It does not address non-cutaneous melanomas, such as melanomas arising from mucosae, ocular melanomas and other rare non-cutaneous sites. It does not cover management of children with cutaneous melanoma.

The update covers new evidence in:

  • pathological reporting
  • sentinel lymph node biopsy and completion lymphadenectomy
  • systemic anticancer therapies
  • follow-up surveillance.

You can find out more here.

Download Guideline

ESMO Guidelines

 

The ESMO Clinical Practice Guidelines on melanoma currently focus on cutaneous melanoma and include information on incidence, diagnosis, staging and risk assessment, treatment, response evaluation and follow-up.

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up- November 2024 

This ESMO CPG provides diagnosis, staging, risk assessment, treatment and follow-up recommendations for cutaneous melanoma. Algorithms for diagnosis, staging, management (stages I-IV and melanoma brain metastases) and follow-up are provided. The authors comprise a multidisciplinary group of experts from Europe, USA and Australia. Recommendations are based on current available scientific data and the authors’ collective expert opinion. All recommendations should be discussed with patients and by a multidisciplinary team.

View cutaneous melanoma guidelines

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee- November 2020

The ESMO consensus conference manuscript on locoregional melanoma was compiled by a multidisciplinary panel of experts and compiles recommendations with supporting evidence on controversial topics in melanoma management. Recommendations for locoregional melanoma in this manuscript include indications for SLNB and RLND, adjuvant targeted versus immunotherapy, adjuvant therapy in specific situations and adjuvant therapy toxicity management.

View locoregional melanoma guidelines

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee-November 2020

The ESMO consensus conference manuscript on metastatic melanoma was compiled by a multidisciplinary panel of experts and compiles recommendations with supporting evidence on controversial topics in melanoma management. Recommendations for metastatic melanoma in this manuscript include targeted versus immunotherapy, treatment sequencing and duration and management of brain metastases.

View metastatic melanoma guidelines